Table 2.

Cost-effectiveness results

Time horizon	Outcome	EVT only	EVT and IVT	Incrementala
90 days	Cost ($)	47,304 (40,784–54,341	55,482 (48,233–63,204)	8,178 (11,591–5,311)
	QALY	0.071 (0.040–0.104)	0.069 (0.038–0.103)	−0.002 (−0.001–0.006)
	ICER ($/QALY gained)	EVT only dominant
1 year	Cost ($)	49,510 (42,917–56,633)	57,751 (50,524–65,546)	8,242 (5,356–11,636)
	QALY	0.435 (0.384–0.488)	0.446 (0.394–0.499)	0.011 (−0.004–0.026)
	ICER ($/QALY gained)	779,899 (−5,080,956 to 7,646,910)
5 years	Costs ($)	59,770 (52,496–67,449)	68,314 (60,491–76,755)	8,544 (5,601–12,005)
	QALY	1.963 (1.740–2.175)	2.204 (1.797–2.242)	0.061 (−0.009 to 0.135)
	ICER ($/QALY gained)	121,081 (−658,201 to 973,710)
20 years	Cost ($)	76,561 (66,607–87,430)	85,611 (75,083–97,146)	9,050 (5,982–12,684)
	QALY	4.158 (3.564–4.474)	4.289 (3.683–4.887)	0.131 (−0.011 to 0.281)
	ICER ($/QALY gained)	−17,767 (−219,217 to 443,659)

ICER, incremental cost-effectiveness ratio.

^aIncremental cost/QALY = cost/QALY of EVT and IVT strategy − cost/QALY of EVT only.

^bDominance means the strategy was less costly and more effective.